Ophthalmology

Opthamology

New opportunities in ophthalmology with sustained drug delivery

We know that creating effective therapies for patients suffering from uncomfortable eye diseases and vision disorders is especially challenging. Working with our pharmaceutical partners, our vision is to create sustained (and sustainable) drug delivery solutions that perform over time - yet require far less frequent dosing from the patient.

We work with partners worldwide across the continuum of healthcare to enable unique drug delivery solutions in ophthalmology that bring progress to life for patients

15+ Years

Of experience in sustained drug delivery applications.

30+ Years

Of experience working with the world’s leading pharmaceutical companies.

150+ Years

Of combined scientific discovery and heritage as part of dsm-firmenich.

Creating next-generation therapies with TheraPEA™

Our TheraPEA™ polyester amide platform is unlocking entirely new therapeutic opportunities for the pharmaceutical industry through its ability to achieve multi-month, controlled drug release.

This highly tunable biomaterial has a zero-order degradation profile and good correlation in-vitro and in-vivo up to 180 days. Furthermore, the unique chemistry of TheraPEA™ changes the game even further through its compatibility with a wide range of challenging Active Pharmaceutical Ingredients.

By developing customized drug delivery solutions with our partners in this way, we can enable longer duration therapies for patients with the potential to increase therapy adherence – and allow for improved clinical outcomes, better healthcare economics and significantly less medical waste.

Learn more about our drug delivery solutions.

age, vision and old people concept - close up of senior woman face and eye

Discover our drug delivery solutions for ophthalmology

One compelling drug delivery therapy potential for ophthalmology comes in wet age-related macular degeneration and diabetic macular edema therapies. The current state of the art therapy consists on an intravitreal injection once every four-to-six weeks to maintain compliance.

An extended duration therapy has the potential to benefit patients; but also the planet - with less materials (eg, packaging and needles) needed to administer the therapy. However, this is not the only solution we offer in ophthalmology - our medical polyurethanes are ideal for use in non-degradable implants thanks to their outstanding biocompatibility and durability.